Figure 1.
Biomarkers under investigation for neoadjuvant immune checkpoint inhibitors in operable NSCLC. PD-L1, programmed cell death-ligand 1; TILs, tumor infiltrating lymphocytes; TLS, tertiary lymphoid structures; TMB, tumor mutation burden; TCR, T cell receptor; ITH, intratumoral heterogeneity; SUVmax, maximum standardized uptake values; NK, natural killer cells; PD-1, programmed cell death-1; NLR, neutrophil to lymphocyte ratio; M,L, myeloid to lymphoid ratio; PLR, platelet to lymphocyte ratio; ctDNA, circulating tumor DNA; bTMB, blood-based tumor mutation burden.